Exchange Traded Concepts LLC Has $1.01 Million Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Exchange Traded Concepts LLC grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 6.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 32,100 shares of the company’s stock after acquiring an additional 1,844 shares during the period. Exchange Traded Concepts LLC owned 0.06% of Harmony Biosciences worth $1,014,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Financial Management Professionals Inc. bought a new position in shares of Harmony Biosciences in the 1st quarter valued at $29,000. Brooklyn Investment Group lifted its stake in shares of Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock valued at $35,000 after acquiring an additional 970 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Harmony Biosciences in the 4th quarter valued at $41,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Harmony Biosciences in the 1st quarter valued at $57,000. Finally, CWM LLC lifted its stake in shares of Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock valued at $90,000 after acquiring an additional 698 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HRMY. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday. Oppenheimer assumed coverage on Harmony Biosciences in a research note on Monday, June 2nd. They issued an “outperform” rating and a $61.00 price target for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $55.00 price objective (up from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. The Goldman Sachs Group initiated coverage on Harmony Biosciences in a report on Thursday, July 10th. They issued a “neutral” rating and a $33.00 price objective for the company. Finally, Truist Financial initiated coverage on Harmony Biosciences in a report on Monday, July 21st. They issued a “buy” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Harmony Biosciences has an average rating of “Buy” and a consensus target price of $51.00.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $32.07 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $35.43 and a two-hundred day moving average price of $33.51. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The company has a market cap of $1.84 billion, a P/E ratio of 10.35, a PEG ratio of 0.38 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. During the same quarter in the previous year, the business posted $1.05 earnings per share. The business’s revenue was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.